Abstract:Background: Immunogenic cell death (ICD) has been categorized as a variant of regulated cell death that is capable of inducing an adaptive immune response. A growing body of evidence has indicated that ICD can modify the tumor immune microenvironment by releasing danger signals or damage-associated molecular patterns (DAMPs), potentially enhancing the efficacy of immunotherapy. Consequently, the identification of biomarkers associated with ICD that can classify patients based on their potential response to ICD immunotherapy would be highly advantageous. Therefore the goal of the study is to better understand and identify what patients with bladder urothelial carcinoma (BLCA) will respond to immunotherapy by analyzing ICD signatures and investigate ICD-related prognostic factors in the context of BLCA. Methods: The data obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases regarding BLCA and normal samples was categorized based on ICD-related genes (IRGs). Specifically, we conducted an immunohistochemical (IHC) experiment to validate the expression levels of Calreticulin (CALR) in both tumor and adjacent tissues, and evaluated its prognostic significance using the Kaplan-Meier (KM) curve. Subsequently, the samples from TCGA were divided into two subtypes using consensus clustering. To obtain a more comprehensive comprehension of the biological functions, we utilized Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA). The calculation of immune landscape between two subtypes was performed through ESTIMATE and CIBERSORT. Risk models were constructed using Cox and Lasso regression and their prognosis predictive ability was evaluated using nomogram, receiver operating characteristic (ROC), and calibration curves. Finally, Tumor Immune Dysfunction and Exclusion (TIDE) algorithms was utilized to predict the response to immunotherapy. Results: A total of 34 IRGs were identified, with most of them exhibiting upregulation in BLCA samples. The expression of CALR was notably higher in BLCA compared to the adjacent tissue, and this increase was associated with an unfavorable prognosis. The differentially expressed genes (DEGs) associated with ICD were linked to various immune-related pathways. The ICD-high subtypes exhibited an immune-activated tumor microenvironment (TME) compared to the ICD-low subtypes. Utilizing three IRGs including CALR , IFNB1 , and IFNG , a risk model was developed to categorize BLCA patients into high- and low-risk groups. The overall survival (OS) was considerably greater in the low-risk group compared to the high-risk group, as evidenced by both the TCGA and GEO cohorts. The risk score was identified as an independent prognostic parameter (all p < 0.001). Our model demonstrated good predictive ability (The area under the ROC curve (AUC), AUC 1 -year= 0.632, AUC 3 -year= 0.637, and AUC 5 -year =0.653). Ultimately, the lower risk score was associated with a more responsive immunotherapy group. Conclusion: The potential of the ICD-based risk signature to function as a marker for evaluating the prognosis and immune landscape in BLCA suggests its usefulness in identifying the suitable population for effective immunotherapy against BLCA.

Development and validation of prognostic index based on immunogenic cell death-related genes with melanoma

A Novel Immunogenic Cell Death-Related Genes Signature for Predicting Prognosis, Immune Landscape and Immunotherapy Effect in Hepatocellular Carcinoma.

A Novel Gene Signature Based on Immunogenic Cell Death-Related Genes Predicts the Prognosis and Immune Infiltration Status of Melanoma Patients

A CD8+ T cell-associated immune gene panel for prediction of the prognosis and immunotherapeutic effect of melanoma

Identification and Validation of Three Risk Models in Skin Melanoma Based on Bioinformatics Analysis

An Immunogenic Cell Death-Related Gene Signature Reflects Immune Landscape and Predicts Prognosis in Melanoma Independently of BRAF V600E Status

Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma

Exploring a Specialized Programmed-Cell Death Patterns to Predict the Prognosis and Sensitivity of Immunotherapy in Cutaneous Melanoma Via Machine Learning.

Construction of an immunogenic cell death-based risk score prognosis model in breast cancer

Exploring the prognostic significance of immunogenic cell death‐related genes as risk biomarkers in cervical cancer

Development and Validation of a Novel T Cell Proliferation-Related Prognostic Model for Predicting Survival and Immunotherapy Benefits in Melanoma

A novel risk-scoring model developed based on tertiary lymphoid structure related genes predict the prognosis and immunotherapeutic efficacy in cutaneous melanoma.

Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma

Immunogenic cell death-related classifications in breast cancer identify precise immunotherapy biomarkers and enable prognostic stratification

Machine learning modeling and prognostic value analysis of invasion-related genes in cutaneous melanoma

A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients

Characteristics and significance of programmed cell death‐related gene expression signature in skin cutaneous melanoma

A novel risk score predicts prognosis in melanoma: The combination of three tumor-infiltrating immune cells and four immune-related genes

An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy—a retrospective cohort study examining 66 circulating immune cell subsets

Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanoma

A Novel Prognostic Model Based on Immunogenic Cell Death-Related Genes for Improved Risk Stratification in Hepatocellular Carcinoma Patients.